These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

599 related articles for article (PubMed ID: 32166558)

  • 1. Recent advances in targeting cancer stem cells using oncolytic viruses.
    Zhang YN; Wang SB; Song SS; Hu PY; Zhou YC; Mou YP; Mou XZ
    Biotechnol Lett; 2020 Jun; 42(6):865-874. PubMed ID: 32166558
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Recent advances in oncolytic virus-based cancer therapy.
    Fu LQ; Wang SB; Cai MH; Wang XJ; Chen JY; Tong XM; Chen XY; Mou XZ
    Virus Res; 2019 Sep; 270():197675. PubMed ID: 31351879
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Improvement of current immunotherapies with engineered oncolytic viruses that target cancer stem cells.
    Soroush A; Shahhosseini R; Ghavamikia N; Hjazi A; Roudaki S; KhalatbariLimaki M; Mirbolouk M; Pakmehr S; Karimi P
    Cell Biochem Funct; 2024 Jun; 42(4):e4055. PubMed ID: 38856033
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Oncolytic virotherapy as promising immunotherapy against cancer: mechanisms of resistance to oncolytic viruses.
    Goradel NH; Alizadeh A; Hosseinzadeh S; Taghipour M; Ghesmati Z; Arashkia A; Negahdari B
    Future Oncol; 2022 Jan; 18(2):245-259. PubMed ID: 34821517
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Concise Review: Targeting Cancer Stem Cells and Their Supporting Niche Using Oncolytic Viruses.
    Crupi MJF; Bell JC; Singaravelu R
    Stem Cells; 2019 Jun; 37(6):716-723. PubMed ID: 30875126
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Viruses as nanomedicine for cancer.
    Badrinath N; Heo J; Yoo SY
    Int J Nanomedicine; 2016; 11():4835-4847. PubMed ID: 27703350
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Oncolytic virotherapy improves immunotherapies targeting cancer stemness in glioblastoma.
    Keshavarz M; Dianat-Moghadam H; Ghorbanhosseini SS; Sarshari B
    Biochim Biophys Acta Gen Subj; 2024 Sep; 1868(9):130662. PubMed ID: 38901497
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Overcoming Barriers in Oncolytic Virotherapy with HDAC Inhibitors and Immune Checkpoint Blockade.
    Marchini A; Scott EM; Rommelaere J
    Viruses; 2016 Jan; 8(1):. PubMed ID: 26751469
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A review exploring the fusion of oncolytic viruses and cancer immunotherapy: An innovative strategy in the realm of cancer treatment.
    Chattopadhyay S; Hazra R; Mallick A; Gayen S; Roy S
    Biochim Biophys Acta Rev Cancer; 2024 Jul; 1879(4):189110. PubMed ID: 38754793
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Arming oncolytic viruses to leverage antitumor immunity.
    de Gruijl TD; Janssen AB; van Beusechem VW
    Expert Opin Biol Ther; 2015 Jul; 15(7):959-71. PubMed ID: 25959450
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The two-faces of NK cells in oncolytic virotherapy.
    Marotel M; Hasim MS; Hagerman A; Ardolino M
    Cytokine Growth Factor Rev; 2020 Dec; 56():59-68. PubMed ID: 32586674
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Therapeutic potency of oncolytic virotherapy in breast cancer targeting, current status and perspective.
    Ebrahimi S; Ghorbani E; Shafiee M; Ryzhikov M; Hassanian SM; Azadmanesh K
    J Cell Biochem; 2019 Mar; 120(3):2801-2809. PubMed ID: 30260014
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Advanced new strategies for metastatic cancer treatment by therapeutic stem cells and oncolytic virotherapy.
    Park GT; Choi KC
    Oncotarget; 2016 Sep; 7(36):58684-58695. PubMed ID: 27494901
    [TBL] [Abstract][Full Text] [Related]  

  • 14. In vitro screen of a small molecule inhibitor drug library identifies multiple compounds that synergize with oncolytic myxoma virus against human brain tumor-initiating cells.
    McKenzie BA; Zemp FJ; Pisklakova A; Narendran A; McFadden G; Lun X; Kenchappa RS; Kurz EU; Forsyth PA
    Neuro Oncol; 2015 Aug; 17(8):1086-94. PubMed ID: 25605818
    [TBL] [Abstract][Full Text] [Related]  

  • 15. SnapShot: Cancer Immunotherapy with Oncolytic Viruses.
    Gujar S; Bell J; Diallo JS
    Cell; 2019 Feb; 176(5):1240-1240.e1. PubMed ID: 30794777
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Therapeutic potency of oncolytic virotherapy-induced cancer stem cells targeting in brain tumors, current status, and perspectives.
    Bahreyni A; Ghorbani E; Fuji H; Ryzhikov M; Khazaei M; Erfani M; Avan A; Hassanian SM; Azadmanesh K
    J Cell Biochem; 2019 Mar; 120(3):2766-2773. PubMed ID: 30321455
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Oncolytic Virotherapy: A New Paradigm in Cancer Immunotherapy.
    Volovat SR; Scripcariu DV; Vasilache IA; Stolniceanu CR; Volovat C; Augustin IG; Volovat CC; Ostafe MR; Andreea-Voichița SG; Bejusca-Vieriu T; Lungulescu CV; Sur D; Boboc D
    Int J Mol Sci; 2024 Jan; 25(2):. PubMed ID: 38256250
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Oncolytic Newcastle disease virus as a prospective anti-cancer therapy. A biologic agent with potential to break therapy resistance.
    Schirrmacher V
    Expert Opin Biol Ther; 2015; 15(12):1757-71. PubMed ID: 26436571
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Updates to the antitumor mechanism of oncolytic virus.
    Bai Y; Hui P; Du X; Su X
    Thorac Cancer; 2019 May; 10(5):1031-1035. PubMed ID: 30900824
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Oncolytic viruses: what to expect from their use in cancer treatment.
    Terrível M; Gromicho C; Matos AM
    Microbiol Immunol; 2020 Jul; 64(7):477-492. PubMed ID: 31663631
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 30.